Systemic Lupus Erythematosus - Pipeline Review, Q1 2011

Document Sample
Systemic Lupus Erythematosus - Pipeline Review, Q1 2011 Powered By Docstoc
					Systemic Lupus Erythematosus – Pipeline Review, Q1 2011




 Systemic Lupus Erythematosus - Pipeline Review, Q1
                       2011
                                                                                          Reference Code: GMDHC033IDB

                                                                                          Publication Date: February 2011




Systemic Lupus Erythematosus – Pipeline Review, Q1 2011                                                               GMDHC033IDB / Pub FEB 2011
© Global Markets Direct. This report is a licensed product and is not to be photocopied
                                                                                                                                         Page(1)
Systemic Lupus Erythematosus – Pipeline Review, Q1 2011



Ta b le o f Co n te n ts
Table of Contents                                                                                               2
List of Tables                                                                                                  5
List of Figures                                                                                                 6
Introduction                                                                                                    7
     Global Markets Direct Report Coverage                                                                      7
Systemic Lupus Erythematosus Overview                                                                           8
Therapeutics Development                                                                                        9
     An Overview of Pipeline Products for Systemic Lupus Erythematosus                                          9
Systemic Lupus Erythematosus Therapeutics under Development by Companies                                       11
Systemic Lupus Erythematosus Therapeutics under Investigation by Universities/Institutes                       14
Late Stage Products                                                                                            17
     Comparative Analysis                                                                                      17
Mid Clinical Stage Products                                                                                    18
     Comparative Analysis                                                                                      18
Early Clinical Stage Products                                                                                  19
     Comparative Analysis                                                                                      19
Discovery and Pre-Clinical Stage Products                                                                      20
     Comparative Analysis                                                                                      20
Companies Involved in Systemic Lupus Erythematosus Therapeutics Development                                    21
     Bristol-Myers Squibb Company                                                                              21
     Boehringer Ingelheim GmbH                                                                                 21
     F. Hoffmann-La Roche Ltd.                                                                                 22
     Amgen Inc.                                                                                                22
     AstraZeneca PLC                                                                                           23
     Eli Lilly and Company                                                                                     23
     GlaxoSmithKline plc                                                                                       24
     Biotest AG                                                                                                24
     Novo Nordisk A/S                                                                                          25
     Plexxikon Inc.                                                                                            25
     Cephalon, Inc.                                                                                            26
     Human Genome Sciences, Inc.                                                                               26
     Pfizer Inc.                                                                                               27
     UCB Group                                                                                                 27
     Celgene Corporation                                                                                       29
     Onyx Pharmaceuticals, Inc.                                                                                29
     Merck KGaA                                                                                                30
     Genesis Research and Development Corporation Ltd.                                                         30
     Hollis-Eden Pharmaceuticals, Inc.                                                                         31
     Active Biotech AB                                                                                         31
     Idera Pharmaceuticals, Inc.                                                                               32
     Compugen Ltd.                                                                                             32
     Dynavax Technologies Corporation                                                                          33
     Protalex, Inc.                                                                                            33
     Neovacs SA                                                                                                34
     CREABILIS Therapeutics S.r.l.                                                                             34
     MAT Biopharma                                                                                             35
     Argos Therapeutics, Inc.                                                                                  35


Systemic Lupus Erythematosus – Pipeline Review, Q1 2011                                    GMDHC033IDB / Pub FEB 2011
© Global Markets Direct. This report is a licensed product and is not to be photocopied                        Page(2)
Systemic Lupus Erythematosus – Pipeline Review, Q1 2011


     Astion Pharma A/S                                                                                          36
     Theraclone Sciences, Inc.                                                                                  36
     Cornerstone Therapeutics Inc.                                                                              37
     ChemoCentryx, Inc.                                                                                         37
     Taligen Therapeutics Inc.                                                                                  38
     Anthera Pharmaceuticals‚ Inc.                                                                              38
     SuppreMol GmbH                                                                                             39
     Advanced Cancer Therapeutics                                                                               39
     Zenyaku Kogyo Co., Ltd.                                                                                    40
     Ampio Pharmaceuticals, Inc.                                                                                40
Universities/Institutes Involved in Systemic Lupus Erythematosus Therapeutics Development                       41
Systemic Lupus Erythematosus - Therapeutics Assessment                                                          43
     Assessment by Monotherapy Products                                                                         43
     Assessment by Combination Products                                                                         44
     Assessment by Route of Administration                                                                      45
     Assessment by Molecule Type                                                                                48
Late Stage Drug Profiles – Companies                                                                            51
     Anti BAFF Human Antibody - Drug Profile                                                                    51
          Product Description                                                                                   51
          Mechanism of Action                                                                                   51
          R&D Progress                                                                                          51
     Atacicept - Drug Profile                                                                                   52
          Product Description                                                                                   52
          Mechanism of Action                                                                                   52
          R&D Progress                                                                                          52
     Benlysta - Drug Profile                                                                                    54
          Product Description                                                                                   54
          Mechanism of Action                                                                                   54
          R&D Progress                                                                                          54
     Epratuzumab - Drug Profile                                                                                 55
          Product Description                                                                                   55
          Mechanism of Action                                                                                   55
          R&D Progress                                                                                          55
     Orencia - Drug Profile                                                                                     57
          Product Description                                                                                   57
          Mechanism of Action                                                                                   57
          R&D Progress                                                                                          57
     Prestara - Drug Profile                                                                                    58
          Product Description                                                                                   58
          Mechanism of Action                                                                                   58
          R&D Progress                                                                                          58
     Rituxan + Prednisone - Drug Profile                                                                        60
          Product Description                                                                                   60
          Mechanism of Action                                                                                   60
          R&D Progress                                                                                          60
     Rituximab + Methylprednisolone - Drug Profile                                                              61
          Product Description                                                                                   61
          Mechanism of Action                                                                                   61




Systemic Lupus Erythematosus – Pipeline Review, Q1 2011                                     GMDHC033IDB / Pub FEB 2011
© Global Markets Direct. This report is a licensed product and is not to be photocopied                         Page(3)
Systemic Lupus Erythematosus – Pipeline Review, Q1 2011


          R&D Progress                                                                                                                       61
Late Stage Drug Profiles – Universities/Institutes                                                                                           62
     Atorvastatin - Drug Profile                                                                                                             62
          Product Description                                                                                                                62
          Mechanism of Action                                                                                                                62
          R&D Progress                                                                                                                       62
     azathioprine - Drug Profile                                                                                                             63
          Product Description                                                                                                                63
          Mechanism of Action                                                                                                                63
          R&D Progress                                                                                                                       63
     cyclophosphamide - Drug Profile                                                                                                         64
          Product Description                                                                                                                64
          Mechanism of Action                                                                                                                64
          R&D Progress                                                                                                                       64
     Cyclophosphamide - Drug Profile                                                                                                         65
          Product Description                                                                                                                65
          Mechanism of Action                                                                                                                65
          R&D Progress                                                                                                                       65
     Infliximab + Azathioprine - Drug Profile                                                                                                66
          Product Description                                                                                                                66
          Mechanism of Action                                                                                                                66
          R&D Progress                                                                                                                       66
     Prevenar + Pneumo23 - Drug Profile                                                                                                      67
          Product Description                                                                                                                67
          Mechanism of Action                                                                                                                67
          R&D Progress                                                                                                                       67
Discontinued Products                                                                                                                        68
     Systemic Lupus Erythematosus - Featured News                                                                                            69
          1. Dec 14, 2010: Anthera Selects Merck BioManufacturing Network As Manufacturing Supplier For A-623                                69
          2. Dec 14, 2010: Immunomedics And UCB Initiate Phase III Program With Epratuzumab In Systemic Lupus Erythematosus                  69
          3. Dec 07, 2010: Argos Initiates Phase I Clinical Trial Of AGS-009 For Treatment Of Systemic Lupus Erythematosus                   70
          4. Dec 03, 2010: GSK And Human Genome Sciences Announce FDA Extension Of Benlysta PDUFA Target Date                                71
          5. Nov 16, 2010: Anthera Suspends Enrollment And Dosing In PEARL-SC Clinical Trial To Address Reports Of Vial Problems             71
          6. Nov 16, 2010: Human Genome Sciences And GSK Announce Vote Of FDA Advisory Committee To Recommend Approval Of Benlysta
          For Systemic Lupus Erythematosus                                                                                       71
          7. Nov 15, 2010: Neovacs Receives DSMB Authorization To Proceed To Fourth Dose Level Of Ifna-Kinoid In Phase I/II Trial In Lupus   72
          8. Oct 06, 2010: Myrexis To Present Oral Anti-Interferon Program At American College of Rheumatology/Association Of Rheumatology
          Health Professionals                                                                                                             72
          9. Sep 27, 2010: Neovacs Receives DSMB Approval For IFNa-Kinoid In Phase I/II Study In Lupus Patients                              73
          10. Aug 19, 2010: HGS A
				
DOCUMENT INFO
Description: Systemic Lupus Erythematosus - Pipeline Review, Q1 2011 Summary Global Markets Direct’s, 'Systemic Lupus Erythematosus - Pipeline Review, Q1 2011', provides an overview of the Systemic Lupus Erythematosus therapeutic pipeline. This report provides information on the therapeutic development for Systemic Lupus Erythematosus, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Systemic Lupus Erythematosus. 'Systemic Lupus Erythematosus - Pipeline Review, Q1 2011' is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - A snapshot of the global therapeutic scenario for Systemic Lupus Erythematosus. - A review of the Systemic Lupus Erythematosus products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Systemic Lupus Erythematosus pipeline on the basis of therapeutic class, route of administration and molecule type. - Profiles of late-stage pipeline products featuring sections on product description, mechanism of action and research & development progress. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Reasons to buy - Identify and understand important and diverse types of therapeutics under develop
BUY THIS DOCUMENT NOW PRICE: $500 100% MONEY BACK GUARANTEED
PARTNER GlobalMarketsDirect
Global Markets Direct is a leading provider of global business intelligence and market analysis. It publishes a range of high quality company and market reports created by its large research and analysis capability and drawing from its extensive unique databases of industry-specific information. Global Markets Direct has a broad range of coverage over key market segments. It has a global scope, covering a broad range of countries constituting more than 90% of global revenues in each of the industries it covers. With a large dedicated research and analysis capability, Global Markets Direct employs rigorous primary and secondary research techniques in developing unique data sets and research materials. Its status as an independent research company allows Analysts to conduct trade interviews with key industry players. Access to unique databases of in-house market information further strengthens research and analysis capabilities. Materials are reviewed shaped by an expert panel of leading industry figures and representatives from key players in the relevant industries